Adamas Pharma shares soar on Parkinson's dyskinesia drug approval

Adamas Pharmaceuticals Inc. shares soared after the drug maker received Food and Drug Administration approval for a one-of-a-kind treatment for the involuntary movements associated with Parkinson's disease. Adamas shares jumped 36% to $19.30 on heavy volume after hours. The company said the FDA approved Gocovri for the treatment of dyskinesia, or the abnormal or involuntary movements, associated with Parkinson's, the only such FDA drug approved for this indication. Adamas expects to roll out Gocovri in the fourth quarter with the full backing of its sales force by January.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.